UroGen Pharma Ltd. (URGN) stock
URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$29.79−0.08 (-0.27%)
Close on Nov 18, 2026Market cap $1.46BP/E –Yield –
UroGen Pharma total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
UroGen Pharma's total debt was $188.73M at Jun 30, 2026. For fiscal 2025 it was $122.21M, up 0.4% from the year before. The highest annual figure on record is $122.21M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $122.21M | +0.4% |
| FY2024 | Dec 31, 2024 | $121.73M | +23.5% |
| FY2023 | Dec 31, 2023 | $98.55M | +1.0% |
| FY2022 | Dec 31, 2022 | $97.54M | – |
| FY2021 | Dec 31, 2021 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $188.73M | +54.1% |
| Q1 FY2026 | Mar 31, 2026 | $189.53M | +55.2% |
| Q4 FY2025 | Dec 31, 2025 | $122.21M | +0.4% |
| Q3 FY2025 | Sep 30, 2025 | $122.11M | +0.3% |
| Q2 FY2025 | Jun 30, 2025 | $122.51M | +25.2% |
| Q1 FY2025 | Mar 31, 2025 | $122.11M | +25.1% |
| Q4 FY2024 | Dec 31, 2024 | $121.73M | +23.5% |
| Q3 FY2024 | Sep 30, 2024 | $121.71M | +23.5% |
| Q2 FY2024 | Jun 30, 2024 | $97.81M | -0.5% |
| Q1 FY2024 | Mar 31, 2024 | $97.59M | -0.4% |
| Q4 FY2023 | Dec 31, 2023 | $98.55M | +1.0% |
| Q3 FY2023 | Sep 30, 2023 | $98.52M | +37.1% |
| Q2 FY2023 | Jun 30, 2023 | $98.30M | +38.1% |
| Q1 FY2023 | Mar 31, 2023 | $97.94M | +38.3% |
| Q4 FY2022 | Dec 31, 2022 | $97.54M | – |
| Q3 FY2022 | Sep 30, 2022 | $71.87M | – |
| Q2 FY2022 | Jun 30, 2022 | $71.20M | – |
| Q1 FY2022 | Mar 31, 2022 | $70.80M | – |
| Q4 FY2021 | Dec 31, 2021 | $0 | – |
See a number that looks wrong?